




Methotrexate

Revised: December 15, 2023.

CASRN: 59-05-2



Drug Levels and Effects

Summary of Use during Lactation

Most sources consider breastfeeding to be contraindicated during maternal high-dose antineoplastic drug therapy with methotrexate. An abstinence period of at least 1 week after chemotherapy doses of methotrexate has been suggested.[1] Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[3]

Maternal doses of methotrexate up to 92 mg (1.12 mg/kg) produce low levels in milk, leading some authors to state that low single or weekly doses, such as those used for ectopic pregnancy or rheumatoid arthritis, are of low risk to the breastfed infant,[4-8] although some expert opinion warns against this use.[9-15] Withholding

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

breastfeeding for 24 hours after a weekly low dose of methotrexate may decrease the infant's dose by 40%.[16-18] If breastfeeding during long-term, low-dose methotrexate use is undertaken, monitoring of the infant's complete blood count and differential and liver enzymes could be considered.

Drug Levels

Methotrexate is partially metabolized to the active metabolite, 7-hydroxymethotrexate, which is detectable in breastmilk.

Maternal Levels. One patient who was 1 month postpartum was given 22.5 mg (15 mg/square meter) methotrexate daily by mouth for choriocarcinoma. Milk was collected at various times of the first 12 days of therapy and measured using an old bioassay. A peak milk level of 2.3 mcg/L occurred 10 hours after the first dose. However, the milk level was relatively constant during the period from 4 to 10 hours after the dose, after which it began to drop. Peak milk levels on the second and third days of administration were 2.7 mcg/L. The authors estimated that a cumulative amount of 0.32 mcg would be excreted in milk during the first 12 hours after this dose.[4] Assuming a maternal weight of 60 kg and using the highest milk level, the worst-case relative infant dose would be about 0.1%

A woman was given a single intramuscular dose of 65 mg (50 mg/square meter) of methotrexate for ectopic pregnancy. Six milk samples were obtained from 1 to 24 hours after the dose. Methotrexate was undetectable (<22.7 mcg/L) in all milk samples.[7]

A woman with rheumatoid arthritis received hydroxychloroquine, sulfasalazine and prednisone 10 mg daily during pregnancy and postpartum. On day 151 postpartum, methotrexate 25 mg was given subcutaneously. Breastmilk samples were obtained at 2, 12 and 24 hours after the dose. Milk levels were 0.05 micromolar (22.7 mcg/L) in all samples which was considered detectable, but not quantifiable. A fully breastfed infant would receive 3.4 mcg/kg in the first 24 hours after administration, or about 1% of the weight-adjusted maternal dosage.[8]

Two lactating women receiving subcutaneous methotrexate 25 mg once weekly donated 4 to 7 milk samples over a 1-week period between doses. Peak breastmilk methotrexate milk concentrations occurred between 1 and 12 hours after the dose and were 4 nmol/L (1.8 mcg/L). Peak breastmilk milk concentrations of the active metabolite, 7-hydroxymethotrexate, occurred at 24 hours after the dose and were 1.8 nmol/L (846 ng/L). Milk methotrexate concentrations were less than 2.5 nmol/L (1.1 mcg/L) during the rest of the dosing interval after the peak. One patient had undetectable (<91 ng/L) milk levels between 5 and 7 days after the dose. The authors estimated that if the peak methotrexate level were sustained throughout the feeding, the relative infant dose would be 0.5% of the weight-adjusted maternal dose and if breastfeeding were withheld for the first 24 hours after the dose, this value would decrease to 0.3% of the weight-adjusted maternal dose.[16]

A woman with placenta accretia received intramuscular methotrexate 92 mg (1.12 mg/kg) daily for 4 days, beginning on day 5 postpartum. On day 2 of therapy, she provided samples of breastmilk at baseline and 1, 2, 4, 8, 12, and 24 hours after the dose. The peak methotrexate milk concentration of 16.9 mcg/L occurred at 2 hours after the dose, which decreased to 4.9 mcg/L at 24 hours. The average methotrexate milk level over the 24-hour period was 8.6 mcg/L. The peak 7-hydroxymethotrexate milk concentration of 3 mcg/L occurred at 1 hour after the dose. The average 7-hydroxymethotrexate milk level over the 24-hour period was 1.5 mcg/L. The estimated daily dosages of methotrexate and 7-hydroxymethotrexate were estimated to be 1.2 mcg/kg and 0.2 mcg/kg, respectively. These represent infant dosages of 0.11% and 0.02% of maternal weight-adjusted dosages.[17]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

On day 151 postpartum, weekly methotrexate 25 mg subcutaneously begun a nursing mother. The estimated intake of the infant at that time was 3.4 mcg/kg in the first 24 hours after administration. The mother continued to breastfeed (extent not stated) for an additional 9 months while receiving subcutaneous methotrexate 25 mg weekly. No adverse effects were noted in the infant.[8]

Three postpartum women were erroneously dispensed methotrexate 2.5 mg daily instead of methylergonovine. They took methotrexate daily for 5, 13 and 15 days, respectively, while they were breastfeeding (extent not stated). Although all of the women developed toxicity and required hospitalization, none of their infants had clinically observable complications.[19]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Rheumatoid Arthritis) [Auranofin](#), [Etanercept](#), [Gold Sodium Thiomalate](#), [Hydroxychloroquine](#), [Infliximab](#), [Penicillamine](#), [Sulfasalazine](#); (Psoriasis) [Adalimumab](#), [Certolizumab Pegol](#), [Etanercept](#), [Infliximab](#), [Phototherapy](#), [Tretinoin](#)

References

1. Pistilli B, Bellettini G, Giovannetti E, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? *Cancer Treat Rev* 2013;39:207-11. PubMed PMID: 23199900.
2. Urbaniak C, McMillan A, Angelini M, et al. Effect of chemotherapy on the microbiota and metabolome of human milk, a case report. *Microbiome* 2014;2:24. PubMed PMID: 25061513.
3. Stopenski S, Aslam A, Zhang X, Cardonick E. After chemotherapy treatment for maternal cancer during pregnancy, is breastfeeding possible? *Breastfeed Med* 2017;12:91-7. PubMed PMID: 28170295.
4. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate in human milk. *Am J Obstet Gynecol* 1972;112:978-80. PubMed PMID: 5042796.
5. Moretti ME, Lee A, Ito S. Which drugs are contraindicated during breastfeeding? *Can Fam Physician* 2000;46:1753-7. PubMed PMID: 11013791.
6. Østensen M. Management of early aggressive rheumatoid arthritis during pregnancy and lactation. *Expert Opin Pharmacother* 2009;10:1469-79. PubMed PMID: 19505214.
7. Tanaka T, Walsh W, Verjee Z, et al. Methotrexate use in a lactating woman with an ectopic pregnancy. *Birth Defects Res A Clin Mol Teratol* 2009;85:494. doi:10.1002/bdra.20605
8. Thorne JC, Nadarajah T, Moretti M, Ito S. Methotrexate use in a breastfeeding patient with rheumatoid arthritis. *J Rheumatol* 2014;41:2332. PubMed PMID: 25362724.
9. Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the Management of IBD in Pregnancy. *Gastroenterology* 2016;150:734-57. PubMed PMID: 26688268.
10. Mahadevan U, Matro R. Care of the pregnant patient with inflammatory bowel disease. *Obstet Gynecol* 2015;126:401-12. PubMed PMID: 26241432.
11. Kavanaugh A, Cush JJ, Ahmed MS, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit: The management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. *Arthritis Care Res (Hoboken)* 2015;67:313-25. PubMed PMID: 25385050.
12. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. *J Crohns Colitis* 2015;9:107-24. PubMed PMID: 25602023.

13. Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: Standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. *Rheumatology (Oxford)* 2016;55:1693-7. PubMed PMID: 26750124.
14. Laube R, Selinger CP, Seow CH, et al. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. *Gut* 2023;72:1040-53. PubMed PMID: 36944479.
15. Torres J, Chaparro M, Julsgaard M, et al. European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. *J Crohns Colitis* 2023;17:1-27. PubMed PMID: 36005814.
16. Delaney S, Colantonio D, Ito S. Methotrexate in breast milk. *Birth Defects Res* 2017;109:711. doi:10.1002/bdr2.1061
17. Baker T, Datta P, Rewers-Felkins K, Hale TW. High-dose methotrexate treatment in a breastfeeding mother with placenta accreta: A case report. *Breastfeed Med* 2018;13:450-2. PubMed PMID: 29985651.
18. CRAT. Méthotrexate – Grossesse et allaitement. 2020. Available at: https://www.lecrat.fr/spip.php?page=article&id_article=469
19. Celentano AA, Ferruzzi MM, Sesana FF, Scaglione FF. Same initial drug name and pharmacist dispensing errors: A case series. *Clin Toxicol* 2023;61 (Suppl 1):102-3. doi:10.1080/15563650.2023.2192024

Substance Identification

Substance Name

Methotrexate

CAS Registry Number

59-05-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Abortifacient Agents, Nonsteroidal

Antimetabolites, Antineoplastic

Antirheumatic Agents

Folic Acid Antagonists

Immunosuppressive Agents